Recent Quotes (30 days)

You have no recent quotes
chg | %

Cardiome Pharma Corp  

(Public, TSE:COM)   Watch this stock  
Find more results for COM
4.06
0.00 (0.00%)
Sep 29 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 3.60 - 12.25
Open     -
Vol / Avg. 0.00/8,140.00
Mkt cap 81.44M
P/E     -
Div/yield     -
EPS -1.45
Shares 20.38M
Beta 0.35
Inst. own     -
Nov 11, 2016
Q3 2016 Cardiome Pharma Corp Earnings Release (Estimated) Add to calendar
Sep 13, 2016
Cardiome Pharma Corp at Rodman & Renshaw Global Investment Conference
Aug 11, 2016
Cardiome Pharma Corp at Canaccord Genuity Growth Conference
Aug 9, 2016
Q2 2016 Cardiome Pharma Corp Earnings Call
Aug 9, 2016
Q2 2016 Cardiome Pharma Corp Earnings Call
Aug 9, 2016
Q2 2016 Cardiome Pharma Corp Earnings Release
  

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -127.12% -116.99%
Operating margin -99.86% -105.60%
EBITD margin - -95.19%
Return on average assets -59.48% -49.75%
Return on average equity -186.84% -131.96%
Employees 85 -
CDP Score - -

Address

1441 Creekside Dr 6th Floor
VANCOUVER, BC V6J 4S7
Canada
+1-604-6776905 (Phone)
+1-604-6776915 (Fax)

Website links

Description

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.

Officers and directors

W. James O'Shea Chairman of the Board
William L. Hunter M.D. President, Chief Executive Officer, Director
Age: 52
Jennifer Archibald Chief Financial Officer
Sheila M. Grant Chief Operating Officer
David D. McMasters J.D. General Counsel
Richard M. Glickman LL.D. Lead Independent Director
Age: 57
Mark H. N. Corrigan M.D. Director
Age: 58
Robert James Meyer M.D. Director
Arthur H. Willms Director
Age: 73
Peter W Roberts CPA Independent Director